Evidence map›Paper›PMID 40018405›Full record

ArticleFrontiers in oncology2025

Case report: Clinical and molecular features of renal gastrointestinal tumor.

Simran Makker, Rayan Rammal, Ping Gu, Guido Dalbagni, Hikmat Al-Ahmadie, Narasimhan P Agaram, Gopa Iyer, Ritesh R Kotecha

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Simran MakkerLaurel Springs School, Ojai, CA, United States.
Rayan RammalDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Ping GuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Guido DalbagniDepartment of Surgery, Sloan Kettering Cancer Center, New York, NY, United States.
Hikmat Al-AhmadieDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Narasimhan P AgaramDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Gopa IyerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Ritesh R KotechaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

While gastrointestinal stromal tumors (GISTs) often arise within the GI tract, it is well known that GISTs may also rarely emanate outside of the digestive system. Prior case reports have documented various primary sites in non-GI organs [extra-intestinal GIST (EGIST)], yet only one report has described a localized GIST of renal origin. Here, we describe a patient who presented with bilateral renal masses who was found to have a large unresectable renal GIST tumor treated with imatinib. We discuss treatment experience and response with systemic therapy and describe molecular data to contextualize this ultra-rare presentation within the landscape of EGIST tumors.

Indexed as

gastrointestinal stromal tumorGISTimatinibKITrenal mass

Identifiers

PMID40018405
PMCPMC11865245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.